{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T19:16:15Z","timestamp":1788290175654,"version":"build-2803163510"},"reference-count":38,"publisher":"European Respiratory Society (ERS)","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,1,26]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Favipiravir has shown efficacy against SARS-CoV-2 in patients &lt;60\u2005years old, but data linking plasma concentrations to clinical outcomes are limited. This study investigated whether favipiravir plasma concentrations influence clinical efficacy and outcomes in patients hospitalised with COVID-19. The main research question was, How can antiviral dosing strategies be optimised to improve pandemic preparedness and treatment efficacy?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult participants were drawn from the PIONEER trial, in which patients received oral favipiravir (1800\u2005mg twice daily for 1\u2005day, then 800\u2005mg twice daily for 9\u2005days) plus standard care. This analysis included patients with confirmed COVID-19 and \u226575% study adherence. Samples were collected between days 5 and 10 post-treatment initiation. The primary outcome was time to clinical improvement. Secondary outcomes included achievement of clinical improvement and mortality risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of 140 patients (50% male; mean\u00b1\n                      <jats:sc>sd<\/jats:sc>\n                      age 59.5\u00b114.8\u2005years), target plasma concentrations were reached in 29 (21%). Mean time to improvement was 7.7\u00b15.9\u2005days in target achievers\n                      <jats:italic>versus<\/jats:italic>\n                      9.1\u00b17.2\u2005days in non-achievers (p=0.26). The target was more often achieved in female (34%) than male (7%) participants (p=0.0002). Plasma concentration inversely correlated with body mass index (r=\u2005\u20130.4, p&lt;0.0001), and with lower body mass index in achievers (26.0\u00b15.1\u2005kg\u00b7m\n                      <jats:sup>\u22122<\/jats:sup>\n                      <jats:italic>versus<\/jats:italic>\n                      30.5\u00b16.9\u2005kg\u00b7m\n                      <jats:sup>\u22122<\/jats:sup>\n                      , p=0.003). Alkaline phosphatase and alanine aminotransferase levels were also lower in achievers (p=0.004 and p=0.02, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Most patients did not reach target favipiravir levels. Concentrations were influenced by sex, body mass index and liver function, confirming the need for pharmacokinetically guided dosing and therapeutic monitoring to optimise antiviral efficacy in future pandemic responses.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.01560-2025","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:15:25Z","timestamp":1774548925000},"page":"01560-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The relationship between plasma favipiravir concentrations and clinical outcomes in COVID-19"],"prefix":"10.1183","volume":"12","author":[{"given":"Rebecca E.","family":"Wawman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-4638","authenticated-orcid":false,"given":"Pallav L.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tonkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4287-149X","authenticated-orcid":false,"given":"Anand","family":"Tana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno R.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Crabtree Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Pertinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9819-7651","authenticated-orcid":false,"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Curley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usman","family":"Arshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Orton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj K.","family":"Bhavsar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026090111401812000_12.4.01560-2025.1","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.93.027"},{"key":"2026090111401812000_12.4.01560-2025.2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2014441117"},{"key":"2026090111401812000_12.4.01560-2025.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18463-z"},{"key":"2026090111401812000_12.4.01560-2025.4","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an anti-influenza drug against life-threatening RNA virus infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol Ther"},{"key":"2026090111401812000_12.4.01560-2025.5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2213-2600(22)00412-X","article-title":"Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care","volume":"11","author":"Shah","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026090111401812000_12.4.01560-2025.6","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1111\/bcp.15227","article-title":"Pharmacokinetic characterization of favipiravir in patients with COVID-19","volume":"88","author":"Gulhan","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"2026090111401812000_12.4.01560-2025.7","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1093\/jac\/dkab135","article-title":"Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5\u2032-triphosphate exposure to support posology for SARS-CoV-2","volume":"76","author":"Pertinez","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2026090111401812000_12.4.01560-2025.8","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mjafi.2020.08.004","article-title":"Favipiravir: a new and emerging antiviral option in COVID-19","volume":"76","author":"Agrawal","year":"2020","journal-title":"Med J Armed Forces India"},{"key":"2026090111401812000_12.4.01560-2025.9","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0364-1"},{"key":"2026090111401812000_12.4.01560-2025.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00649-13"},{"key":"2026090111401812000_12.4.01560-2025.11","doi-asserted-by":"crossref","unstructured":"Shannon A , Selisko B , Le N , et al. Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase. bioRxiv 2020, preprint [10.1101\/2020.05.15.098731].","DOI":"10.1101\/2020.05.15.098731"},{"key":"2026090111401812000_12.4.01560-2025.12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.4.977-981.2002"},{"key":"2026090111401812000_12.4.01560-2025.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.02.014"},{"key":"2026090111401812000_12.4.01560-2025.14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005389"},{"key":"2026090111401812000_12.4.01560-2025.15","doi-asserted-by":"crossref","unstructured":"Curley P , Neary M , Arshad U , et al. Development of a highly sensitive bioanalytical assay for the quantification of favipiravir. bioRxiv 2021, preprint [http:\/\/doi.org\/10.1101\/2021.02.03.429628].","DOI":"10.1101\/2021.02.03.429628"},{"key":"2026090111401812000_12.4.01560-2025.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"2026090111401812000_12.4.01560-2025.17","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq447"},{"key":"2026090111401812000_12.4.01560-2025.18","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.44.101802.121453"},{"key":"2026090111401812000_12.4.01560-2025.19","doi-asserted-by":"publisher","DOI":"10.3109\/03602532.2011.560606"},{"key":"2026090111401812000_12.4.01560-2025.20","doi-asserted-by":"publisher","DOI":"10.2174\/187231208785425818"},{"key":"2026090111401812000_12.4.01560-2025.21","doi-asserted-by":"publisher","DOI":"10.4172\/2157-7609.1000119"},{"key":"2026090111401812000_12.4.01560-2025.22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010814-124354"},{"key":"2026090111401812000_12.4.01560-2025.23","doi-asserted-by":"publisher","DOI":"10.1007\/BF03261929"},{"key":"2026090111401812000_12.4.01560-2025.24","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1111\/bcp.14735","article-title":"Effect of lipophilicity on drug distribution and elimination: influence of obesity","volume":"87","author":"Bruno","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026090111401812000_12.4.01560-2025.25","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-018-0189-3"},{"key":"2026090111401812000_12.4.01560-2025.26","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00702-014-1317-9","article-title":"Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI","volume":"122","author":"Sigurdsson","year":"2015","journal-title":"J Neural Transm (Vienna)"},{"key":"2026090111401812000_12.4.01560-2025.27","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.1.121"},{"key":"2026090111401812000_12.4.01560-2025.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2008.07.007"},{"key":"2026090111401812000_12.4.01560-2025.29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.5507\/bp.2017.026","article-title":"Effects of obesity on liver cytochromes P450 in various animal models","volume":"161","author":"Tomankova","year":"2017","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"2026090111401812000_12.4.01560-2025.30","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.570331"},{"key":"2026090111401812000_12.4.01560-2025.31","doi-asserted-by":"publisher","DOI":"10.2337\/db06-1656"},{"key":"2026090111401812000_12.4.01560-2025.32","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.45.120403.095843"},{"key":"2026090111401812000_12.4.01560-2025.33","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-13-29"},{"key":"2026090111401812000_12.4.01560-2025.34","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1253\/circj.CJ-14-0343","article-title":"Roles of xenobiotic receptors in vascular pathophysiology","volume":"78","author":"Xiao","year":"2014","journal-title":"Circ J"},{"key":"2026090111401812000_12.4.01560-2025.35","doi-asserted-by":"publisher","DOI":"10.1016\/bs.apha.2015.04.001"},{"key":"2026090111401812000_12.4.01560-2025.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.10.037"},{"key":"2026090111401812000_12.4.01560-2025.37","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v13.i11.1688"},{"key":"2026090111401812000_12.4.01560-2025.38","doi-asserted-by":"crossref","first-page":"e1233","DOI":"10.1002\/prp2.1233","article-title":"Favipiravir pharmacokinetics in Thai adults with mild COVID-19: a sub-study of interpatient variability and ethnic differences in exposure","volume":"12","author":"Prasanchaimontri","year":"2024","journal-title":"Pharmacol Res Perspect"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.01560-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:40:24Z","timestamp":1788288024000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.01560-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,27]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1183\/23120541.01560-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.01560-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]}}}